Ion channel receptor and uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorDavid J. Glass
Life of this patent
Estimating the term…
Abstract
The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MINC102. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MINC102 gene product. The present invention also provides for diagnostic and therapeutic methods for treating muscle atrophy by inhibiting expression or activity of MINC102.
Claims17
An isolated nucleic acid molecule having a sequence selected from the group consisting of:
- (a) SEQ ID NO:1;
- (b) a nucleotide sequence that hybridizes under stringent conditions to the complement of the nucleotide sequence of (a) and which encodes MINC102, wherein the stringent conditions are 30% formamide in 5×SSPE (0.18 M NaCl, 0.01 M NaPO4, pH 7.7, 0.001 M EDTA) buffer at a temperature of 42° C. and remaining bound when subject to washing at 42° C. with 0.2×SSPE;
- or
- (c) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleic acid of (a) or (b) and which encodes MINC102.
A human MINC102 protein comprising SEQ ID NO:2, or biologically active fragments thereof.
A method for identifying an agent capable of inhibiting the expression or activity of MINC102, comprising:
- (a) administering a test agent to an animal expressing a MINC102 protein, or protein fragment;
- and
- (b) determining the ability of the test agent to inhibit MINC102 expression or activity.
A therapeutic method for treating, inhibiting, or reducing muscle atrophy in a subject in need thereof, comprising administering a therapeutically effective amount of an agent capable of inhibiting MINC102 activity or expression.
An isolated nucleic acid sequence encoding a mouse MINC102, comprising:
- (a) SEQ ID NO:3;
- or
- (b) a nucleotide sequence which, but for the degeneracy of the genetic code, would hybridize to the complement of SEQ ID NO:3, and which encodes a molecule having the biological activity of MINC102.
A transgenic animal, comprising a modification of an endogenous MINC102 gene.
Dependencies are inferred from the claim text.